Establishing 3D organotypic models isn’t always straightforward. The research involves investigating a huge array of variables to assess the optimal conditions in terms of time points, media constituents, cell types, seeding densities and co-culture cell ratios as well as the most appropriate endpoints and analytical techniques. Cyprotex have spent considerable time and effort establishing robust in vitro 3D models for predicting safety of new chemical entities.
A recent poster presented by Cyprotex at the NC3Rs / Safety Pharmacology Society Regional Meeting in Coventry in the UK in May 2017 describes Cyprotex’s latest research in the field of 3D liver, cardiac and kidney co-culture models. These models, which are formed from primary cells or induced pluripotent stem cell (iPSC) derived cells, better mimic the in vivo cellular environment and often have improved predictivity when compared to the 2D monolayer equivalents.